CN115175677A - 布鲁顿氏酪氨酸激酶抑制剂的给药 - Google Patents

布鲁顿氏酪氨酸激酶抑制剂的给药 Download PDF

Info

Publication number
CN115175677A
CN115175677A CN202080095816.0A CN202080095816A CN115175677A CN 115175677 A CN115175677 A CN 115175677A CN 202080095816 A CN202080095816 A CN 202080095816A CN 115175677 A CN115175677 A CN 115175677A
Authority
CN
China
Prior art keywords
administered
day
cycle
days
btk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095816.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·J·布兰德胡伯
N·C·Y·库
N·南达
S·A·史密斯
D·蔡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosso Oncology Co
Original Assignee
Rosso Oncology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosso Oncology Co filed Critical Rosso Oncology Co
Publication of CN115175677A publication Critical patent/CN115175677A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080095816.0A 2019-12-06 2020-12-03 布鲁顿氏酪氨酸激酶抑制剂的给药 Pending CN115175677A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962944674P 2019-12-06 2019-12-06
US62/944674 2019-12-06
US202063077996P 2020-09-14 2020-09-14
US63/077996 2020-09-14
US202063109698P 2020-11-04 2020-11-04
US63/109698 2020-11-04
PCT/US2020/063089 WO2021113497A1 (en) 2019-12-06 2020-12-03 Dosing of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
CN115175677A true CN115175677A (zh) 2022-10-11

Family

ID=73854977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095816.0A Pending CN115175677A (zh) 2019-12-06 2020-12-03 布鲁顿氏酪氨酸激酶抑制剂的给药

Country Status (10)

Country Link
US (1) US12551463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069219A1 (cg-RX-API-DMAC7.html)
JP (3) JP7142173B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220100992A (cg-RX-API-DMAC7.html)
CN (1) CN115175677A (cg-RX-API-DMAC7.html)
AU (2) AU2020397034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009716A2 (cg-RX-API-DMAC7.html)
IL (1) IL292882B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006631A (cg-RX-API-DMAC7.html)
WO (1) WO2021113497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN114605327B (zh) * 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Also Published As

Publication number Publication date
EP4069219A1 (en) 2022-10-12
KR20230127372A (ko) 2023-08-31
AU2024201263B2 (en) 2025-05-01
JP2022177119A (ja) 2022-11-30
IL292882B1 (en) 2026-05-01
US12551463B2 (en) 2026-02-17
AU2020397034A1 (en) 2022-07-21
AU2024201263A1 (en) 2024-03-14
BR112022009716A2 (pt) 2022-08-09
IL292882A (en) 2022-07-01
JP2025098099A (ja) 2025-07-01
NZ788615A (en) 2024-10-25
CA3160417A1 (en) 2021-06-10
US20230041515A1 (en) 2023-02-09
MX2022006631A (es) 2022-09-07
AU2020397034B2 (en) 2023-12-07
JP7142173B2 (ja) 2022-09-26
JP7654604B2 (ja) 2025-04-01
KR20220100992A (ko) 2022-07-18
WO2021113497A1 (en) 2021-06-10
JP2022518974A (ja) 2022-03-17

Similar Documents

Publication Publication Date Title
US9364476B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
UA125216C2 (uk) Комбінована терапія
KR20250164332A (ko) 골수증식성 장애를 치료하는 방법
JP2025098099A (ja) ブルトン型チロシンキナーゼ阻害剤の投薬
CN113226320A (zh) Mdm2抑制剂的延长的低剂量方案
WO2020239558A1 (en) Combination therapies using cdk inhibitors
Owen et al. Novel therapies for chronic lymphocytic leukemia: a Canadian perspective
CN113730572A (zh) 含有抗egfr抗体或其片段的联合用药物
Jeyakumar et al. B cell receptor inhibition as a target for CLL therapy
KR20220148826A (ko) 브루톤 티로신 키나아제의 저해제를 이용하여 원발성 진행형 다발성 경화증을 치료하는 방법
US20140140991A1 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
Pallasch et al. Incorporating targeted agents into future therapy of chronic lymphocytic leukemia
CA3160417C (en) Dosing of a bruton's tyrosine kinase inhibitor
CA3255718A1 (en) Polytherapy involving GDC-6036 and GDC-0077 for cancer treatment
AU2021320130B2 (en) Treatment of CLL
NZ788615A9 (en) Dosing of a bruton's tyrosine kinase inhibitor
EA046722B1 (ru) Введение доз ингибитора тирозинкиназы брутона
AU2012321091B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
EA051944B1 (ru) Введение доз ингибитора тирозинкиназы брутона
Sethi et al. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination